GLP1R and obesity disorder: Despite encouraging recent data showing decreases in BMI with glucagon-like peptide-1 receptor agonists in adolescents with obesity (10), non-surgical treatments for obesity such as diet, exercise, and behavioral modifications have generally been disappointing, with only modest outcome benefits in both adults and children (11–13).